Thrombotargets Corp.
This article was originally published in Start Up
Executive Summary
Company executives at Thrombotargets hit the ground running upon its 2005 founding in Barcelona, Spain. In two years, they have developed a pipeline of 11 hemostatics, anticoagulants, antiplatelets and fibrinolytics, all enabled by the company's proprietary high-throughput screening process, BioPlatformScreen. Thrombotargets is now preparing for clinical trials of its lead candidate, an antihemorrhagic human recombinant protein that has received FDA orphan drug status for two indications.
You may also be interested in...
ZymoGenetics Experiences a Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.
ZymoGenetics' Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.